Literature DB >> 812760

Hepatic toxicity in the rhesus monkey treated with chenodeoxycholic acid for 6 months: biochemical and ultrastructural studies.

H Dyrszka, G Salen, F G Zaki, T Chen, E H Mosbach.   

Abstract

The long term administration of chenodeoxycholic acid in man has to be regarded with caution because chenodeoxycholic acid has caused liver damage in various species of animals, including primates. To study the effect of three doses of chenodeoxycholic acid (10, 40, and 100 mg per kg per day) on hepatic function and morphology, biliary bile acid composition and the reversibility of changes were investigated in 22 rhesus monkeys. After 6 months of treatment with 40 and 100 mg per kg per day, bile duct proliferation, portal tract inflammation and fibrosis, bile canalicular bleb formation, and hypertrophy of the smooth endoplasmic reticulum were associated with elevated serum levels of oxaloacetic transaminase, glutamic pyruvic transaminase, and leucine aminopeptidase. In the bile, the proportion of chenodeoxycholic acid and its bacterial metabolite, lithocholic acid, rose to approximately 85 and 10% of the total bile acids. After chenodeoxycholic acid was withdrawn for 3 months, the hepatic morphological lesions persisted in some animals although biliary bile acid composition returned to normal. No hepatic abnormalities were seen in the animals treated with 10 mg per kg per day. The findings suggest that long term treatment of rhesus monkeys with high doses of chenodeoxycholic acid results in severe hepatic histological lesions that can persist after discontinuation of the bile acid.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 812760

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

1.  Effect of gallstone-dissolution therapy on human liver structure.

Authors:  M C Bateson; D Hopwood; I A Bouchier
Journal:  Am J Dig Dis       Date:  1977-04

2.  Lithocholate metabolism during chemotherapy for gallstone dissolution. 2. Absorption and sulphation.

Authors:  R N Allan; J L Thistle; A F Hofmann
Journal:  Gut       Date:  1976-06       Impact factor: 23.059

3.  Effect of taurolithocholate on in vivo sulfation and glucuronidation of acetaminophen in rats.

Authors:  R E Galinsky; B Chałasinska
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

4.  Bile acid conjugation in the chimpanzee: effective sulfation of lithocholic acid.

Authors:  M Schwenk; A F Hofmann; G L Carlson; J A Carter; F Coulston; H Greim
Journal:  Arch Toxicol       Date:  1978-04-27       Impact factor: 5.153

5.  Effect of coprophagy on bile acid metabolism in the rabbit.

Authors:  K Yahiro; T Setoguchi; T Katsuki
Journal:  Gastroenterol Jpn       Date:  1979-12

Review 6.  Bile salts of vertebrates: structural variation and possible evolutionary significance.

Authors:  Alan F Hofmann; Lee R Hagey; Matthew D Krasowski
Journal:  J Lipid Res       Date:  2009-07-28       Impact factor: 5.922

7.  Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones.

Authors:  J W Marks; S O Sue; B J Pearlman; G G Bonorris; P Varady; J M Lachin; L J Schoenfield
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 8.  Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

Authors:  J H Iser; A Sali
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

9.  Clinical studies on dissolution of gallstones using ursodeoxycholic acid.

Authors:  M Okumura; K Tanikawa; Y Chúman; T Kóji; S Nakagawa; Y Nakamura; H Iino; S Yamasaki; T Hisatsugu
Journal:  Gastroenterol Jpn       Date:  1977

10.  Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey.

Authors:  F Bazzoli; A Roda; H Fromm; R P Sarva; E Roda; L Barbara
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.